H. David Inzunza

Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan et al. · New England Journal of Medicine · 2013 · 4.2K citations · Full text

Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma

Jeffrey S. Weber, Ragini R. Kudchadkar, Bin Yu et al. · Journal of Clinical Oncology · 2013 · 528 citations · Full text

Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

Geoffrey T. Gibney, Ragini R. Kudchadkar, Ronald C. DeConti et al. · Clinical Cancer Research · 2014 · 254 citations · Full text

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer

Thérèse Phillips, Pauline Simmons, H. David Inzunza et al. · Applied immunohistochemistry & molecular morphology · 2015 · 190 citations · Full text

Cancer Immunosurveillance, Cancer Detection, Medicine +15

CD32B, the human inhibitory Fc-γ receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma

Christopher T. Rankin, Maria-Concetta Verı́, Sergey Gorlatov et al. · Blood · 2006 · 88 citations · Full text